摘要
研究肾细胞癌(renalcellcarcinoma ,RCC)患者的肿瘤免疫状况,为RCC的早期诊断、预后判断及免疫治疗打下良好的理论基础。取4 0例RCC癌患者及2 0例正常对照,利用酶联免疫吸附试验方法分别测定所有研究对象外周血IFN γIL 10水平。结果显示:①RCC患者组外周血IFN γ为(74 6 2±9 4 3)pg ml,明显低于对照组(96 88±4 0 2 7)pg ml,P <0 0 1;而IL 10为(95 88±32 87)pg ml,明显高于对照组(71 19±14 10 )pg ml,P <0 0 1;②4 0例RCC患者外周血IFN γ随RCC分期升高不断降低;而IL 10随分期升高而不断升高。结果表明:RCC患者血浆IFN γ水平降低、IL 10水平升高,RCC患者Th2类细胞因子呈强势表达状态,说明了RCC患者处于肿瘤免疫抑制状态。随着RCC的进展,RCC患者肿瘤免疫抑制加强。
To study anti-tumor immunity capacity of patients with renal cell carcinoma (RCC), create theory basis for early diagnosis, prognosis judgement and immunotherapy of RCC. 40 patients with RCC and 20 controls were studied, the levels of interferon-γ and interleukin-10 were investigated by ELISA in peripheral blood of all. Results as follow IFN-γ level(74.62±9.43)pg/mlin peripheral blood of patients with RCC was significantly lower (P<0.01) than that(96.88±40.27)pg/ml in controls, however, IL-10 level(95.88±32.87)pg/ml of patients with RCC was apparently higher(P<0.01)than that of controls (71.19±14.10)pg/ml. IFN-γ and IL-10 levels varied according to different stages, IFN-γ level decreased with higher stage, while IL-10 level increased. Higher IL-10 level and lower IFN-γ level of peripheral blood in patients with RCC showed that Th2 cytokines expression was enhanced in patients with RCC, suggesting that their immunity capacity was suppressed. With tumor progressing, immunity suppression increased.
出处
《北京生物医学工程》
2005年第3期217-219,共3页
Beijing Biomedical Engineering
